JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List

Stock News07-10

The stock price of JUNSHI BIO (01877) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.

The catalyst for the move is news that the company's product, Junmaikang® (adalimumab injection), has been included in the updated National Essential Drug List (2026 edition). This inclusion is expected to benefit patients with autoimmune chronic conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

Junmaikang®, co-developed by JUNSHI BIO and Mabwell, was first approved for marketing in China in 2022 and is already covered under the National Reimbursement Drug List (Class B). The product has now received approval for eight indications domestically, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.

Furthermore, the product's commercial partnerships extend to 17 countries, with marketing applications submitted in seven nations. It has already received approval for market entry in Indonesia in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179369678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179369678","market":"fut","top_or_hot":-1,"title":"JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List","media":"Stock News","content":"<p>The stock price of <b>JUNSHI BIO</b> (<b>01877</b>) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.<br><br>The catalyst for the move is news that the company's product, Junmaikang® (adalimumab injection), has been included in the updated National Essential Drug List (2026 edition). This inclusion is expected to benefit patients with autoimmune chronic conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.<br><br>Junmaikang®, co-developed by <b>JUNSHI BIO</b> and Mabwell, was first approved for marketing in China in 2022 and is already covered under the National Reimbursement Drug List (Class B). The product has now received approval for eight indications domestically, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.<br><br>Furthermore, the product's commercial partnerships extend to 17 countries, with marketing applications submitted in seven nations. It has already received approval for market entry in Indonesia in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-10 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The stock price of <b>JUNSHI BIO</b> (<b>01877</b>) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.<br><br>The catalyst for the move is news that the company's product, Junmaikang® (adalimumab injection), has been included in the updated National Essential Drug List (2026 edition). This inclusion is expected to benefit patients with autoimmune chronic conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.<br><br>Junmaikang®, co-developed by <b>JUNSHI BIO</b> and Mabwell, was first approved for marketing in China in 2022 and is already covered under the National Reimbursement Drug List (Class B). The product has now received approval for eight indications domestically, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.<br><br>Furthermore, the product's commercial partnerships extend to 17 countries, with marketing applications submitted in seven nations. It has already received approval for market entry in Indonesia in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1179369678","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179369678","pubTimestamp":1783650988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The stock price of JUNSHI BIO (01877) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.The catalyst for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","KCAI":"KraneShares China Alpha Index ETF","01877":"君实生物","BK1161":"生物科技","BK1515":"抗疫概念","BK4588":"碎股"},"translate_title":"君迈康纳入君实生物股价飙升逾5%®国家基本药物目录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"01877":1,"VXUS":1},"content_text":"The stock price of JUNSHI BIO (01877) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.The catalyst for the move is news that the company's product, Junmaikang® (adalimumab injection), has been included in the updated National Essential Drug List (2026 edition). This inclusion is expected to benefit patients with autoimmune chronic conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.Junmaikang®, co-developed by JUNSHI BIO and Mabwell, was first approved for marketing in China in 2022 and is already covered under the National Reimbursement Drug List (Class B). The product has now received approval for eight indications domestically, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.Furthermore, the product's commercial partnerships extend to 17 countries, with marketing applications submitted in seven nations. It has already received approval for market entry in Indonesia in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179369678","isCrawlerRequest":true}